Georgia's Online Cancer Information Center


back

Acute Lymphoblastic Leukemia Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Acute Lymphoblastic Leukemia
Cancer Type = Acute Lymphoblastic Leukemia
NCI ID Cancer Type Trial Name
There are currently 6 active Acute Lymphoblastic Leukemia clinical trials in Georgia.
NCI ID Cancer Type Trial Name
1.
A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Cancer Type
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Leukemia, Lymphoma, Neuroblastoma
NCT ID
NCT03236857
Protocol IDs
M13-833
NCI-2017-02027
2017-000439-14
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
2.
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
Cancer Type
Acute Lymphoblastic Leukemia
NCT ID
NCT02723994
Protocol IDs
INCB 18424-269
NCI-2016-01687
AALL1521
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
3.
A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapse of Acute Lymphoblastic Leukemia
Cancer Type
Acute Lymphoblastic Leukemia, Leukemia, Lymphoma
NCT ID
NCT02879643
Protocol IDs
T2012-002
NCI-2016-01398
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
4.
Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients
Cancer Type
Acute Lymphoblastic Leukemia
NCT ID
NCT01595048
Protocol IDs
ANHL1131
NCI-2012-01963
CDR0000732604
U10CA098543
COG-ANHL1131
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
5.
Matched Targeted Therapy (MTT) Recommendation for Patients with Recurrent, Refractory, or High Risk Leukemias
Cancer Type
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS)
NCT ID
NCT02670525
Protocol IDs
15-384
NCI-2016-00336
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
6.
Phase 1b/2 Study of Carfilzomib in Combination With Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (UK R3 Induction Backbone) in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Cancer Type
Acute Lymphoblastic Leukemia
NCT ID
NCT02303821
Protocol IDs
CFZ008
NCI-2014-02601
2014-001633-84
About Us Research Resources & Education Screening & Genetics Clinical Trials & Providers Cancer Navigators Survivorship Media, News & Events Contact Us Donate Take Our Survey Link to Us

Research

Screening & Genetics

Clinical Trials & Providers

Survivorship

About Us

Resources & Education

Media, News & Events

Patient Navigation

Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.